(6-chloro-9H-carbazol-3-yl)-(3-hydroxy-8-azabicyclo[3.2.1]oct-8-yl)methanone | 1064686-51-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (6-chloro-9H-carbazol-3-yl)-(3-hydroxy-8-azabicyclo[3.2.1]oct-8-yl)methanone
• 英文别名: (6-chloro-9H-carbazol-3-yl)-(3-hydroxy-8-azabicyclo[3.2.1]octan-8-yl)methanone
• CAS: 1064686-51-6
• 化学式: C₂₀H₁₉ClN₂O₂
• 分子量: 354.836
• InChiKey: AYQLIHUZUBKPPZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  25
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  56.3
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• 11BETA-HSD1 ACTIVE COMPOUNDS
  申请人：Ebdrup Soren

  公开号：US20100056600A1

  公开（公告）日：2010-03-04

  A novel class of compounds of the general formula (I), their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds modulate the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, e.g. the metabolic syndrome.

  本文描述了一类通式为(I)的新化合物，它们在治疗中的应用，包括含有这些化合物的药物组合物，以及它们在制造药物中的应用。这些化合物调节11β-羟基类固醇脱氢酶1型（11βHSD1）的活性，因此在治疗调节该酶活性有益的疾病，如代谢综合征中有用。
• [EN] 11BETA-HSD1 ACTIVE COMPOUNDS<br/>[FR] COMPOSÉS ACTIFS SUR 11BÊTA-HSD1
  申请人：TRANSTECH PHARMA INC

  公开号：WO2008119017A1

  公开（公告）日：2008-10-02

  [EN] A novel class of compounds of the general formula (I), their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds modulate the activity of 11ß -hydroxysteroid dehydrogenase type 1 (11ßHSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, e.g. the metabolic syndrome.
  [FR] L'invention concerne une classe novatrice de composés représentés par la formule générale (I), leur utilisation en thérapie, des compositions pharmaceutiques comprenant les composés, ainsi que leur utilisation dans la fabrication de médicaments. Les présents composés modulent l'activité de l'hydroxystéroïde déshydrogénase 11b de type 1 (11bHSD1) et sont donc utiles dans le traitement des maladies dans lesquelles une modulation est bénéfique, par exemple, le syndrome métabolique.